Clinical trials: Uveitis, Anterior
Behcet Disease
A Study to Evaluate Efficacy and Safety of Infliximab in Participant With Moderate-to-Severe Refractory Intestinal Behcet's Disease
The purpose of this study is to evaluate the efficacy of infliximab in induction regimen by assessing the mean decrease in Disease Activity Index for intestinal Behcet's disease (DAIBD) score of 20 or more in participants with…
- Trial name
- BEGIN (NCT02505568)
- Testing
- Infliximab
- Where
- 5 sites in South Korea
- Volunteers
- 33 people
- Sponsor
- Janssen Korea, Ltd., Korea
Choroiditis, Iridocyclitis
Evaluation and Treatment of Patients With Inflammatory Eye Diseases
This study offers evaluation and treatment for patients with inflammatory eye diseases, such as uveitis. The protocol is not designed to test new treatments; rather, patients will receive current standard of care treatments.
- Conditions
- Choroiditis, Iridocyclitis, Iritis, Retinal Disease
- Trial name
- NCT00006188
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- National Eye Institute (NEI)
Behcet Syndrome, Behcet Disease
Topical Pentoxifylline Gel on Behcet's Disease Genital Ulcers
Behçet's Disease (BD) is a complex, chronic, relapsing, multi-system inflammatory disorder that is characterized by oral ulcers, genital ulcers in addition to ocular and skin symptoms.
- Trial name
- NCT04186559
- Testing
- Topical Pentoxifylline Gel (Vehicle +PTX)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Silk Road Therapies, Inc.
Behçet Disease
Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease
The purpose of this study is to evaluate the proof of concept of efficacy of ustekinumab in subjects with Behçet disease, including patients with oral ulcers (STELABEC-1) and patients with active posterior uveitis or panuveitis…
- Trial name
- STELABEC (NCT02648581)
- Testing
- Subcutaneous Ustekinumab
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Anterior Uveitis
Exploratory Study on Topical ESBA105 in Acute Anterior Uveitis
The purpose of this study is to determine whether ESBA105, a topically applied TNF-alpha inhibitor, is safe and clinically active when applied to the eye of patients suffering from acute anterior uveitis
- Trial name
- NCT00823173
- Testing
- ESBA105
- Where
- 3 sites in Germany
- Volunteers
- 9 people
- Sponsor
- ESBATech AG
Rheumatoid Arthritis, Spondylitis, Ankylosing
Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases
Introduction: Patients with autoimmune rheumatic diseases (ARDs), rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), psoriatic arthritis (PAs), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), primary…
- Conditions
- Rheumatoid Arthritis, Spondylitis, Ankylosing, Spondyloarthritis, Systemic Lupus Erythematosus
- Trial name
- RZVRheum (NCT05879419)
- Testing
- Recombinant Herpes Zoster Vaccine (RZV), MTX Discontinuation, MMF Discontinuation
- Where
- Brazil
- Volunteers
- 2,005 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Uveitis, Diabetic Retinopathy
Biomarkers of Common Eye Diseases
To identify biomarkers of common eye diseases based on single-cell sequencing technologies using PBMC samples. These diseases include uveitis, diabetic retinopathy, age-related macular degeneration and polypoid choroidal…
- Conditions
- Uveitis, Diabetic Retinopathy, Age-related Macular Degeneration, Polypoidal Choroidal Vasculopathy
- Trial name
- NCT04101604
- Testing
- Collection of blood samples
- Where
- China
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Uveitis
Efficacy, Safety and Costs of Methotrexate, Adalimumab, or Their Combination in Non-infectious Non-anterior Uveitis
Introduction: Non-infectious uveitis (NIUs) include a heterogeneous group of sight-threatening conditions. NIUs can be highly disabling and be associated with a profound impact in the quality-of-life (QoL) and wellbeing.
- Trial name
- Co-THEIA (NCT04798755)
- Testing
- Methotrexate, Adalimumab, Adalimumab+Methotrexate
- Where
- 14 sites in Spain
- Volunteers
- 192 people
- Sponsor
- Hospital San Carlos, Madrid
Vasculitis, Systemic Vasculitis
Journey of Patients With Vasculitis From First Symptom to Diagnosis
This study seeks to understand the journey that patients eventually are diagnosed with vasculitis experience in the period prior to their formal diagnosis by a healthcare provider.
- Conditions
- Vasculitis, Systemic Vasculitis, Behcet's Disease, CNS Vasculitis
- Trial name
- NCT03410290
- Testing
- Online Questionnaire
- Where
- United States
- Volunteers
- 456 people
- Sponsor
- University of Pennsylvania
Behcet Syndrome
Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome
In patients with Behçet's syndrome (BS), deep venous thrombosis (DVT) is thought to result from inflammation of the vessel wall rather than hyper coagulability.
- Trial name
- ACTOR (NCT06780462)
- Testing
- Corticosteroids + Rivaroxaban, Corticosteroids alone
- Where
- 17 sites in France
- Volunteers
- 134 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Behçet Disease
Serum EBI-3 Protein Levels in Behçet's Disease
This cross-sectional study aims to evaluate serum Epstein-Barr virus-induced gene 3 (EBI-3) protein levels in patients with Behçet's disease compared with healthy controls.
- Trial name
- NCT07845162
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Assiut University
Behçet's Syndrome
A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease
The main objective of this study is to evaluate the efficacy and safety of apremilast in the treatment of oral ulcers in adults with active Behçet's disease (BD).
- Trial name
- NCT02307513
- Testing
- Apremilast
- Where
- 63 sites in United States, France and 8 more
- Volunteers
- 207 people
- Sponsor
- Amgen